# Vitamin D ameliorates prediabetic cardiac injure via modulation of the ErbB4/ferroptosis signaling axis

**Authors:** Yufan Miao, Yujing Zhang, Luoya Zhang, Hao Chen, Lulu Tang, Wenjie Li, Chenxi Gu, Lili Lang, Xing Li, Hanlu Song

PMC · DOI: 10.3389/fimmu.2025.1626295 · Frontiers in Immunology · 2025-07-17

## TL;DR

Vitamin D helps protect the heart in prediabetic conditions by affecting the ErbB4/ferroptosis signaling pathway.

## Contribution

This study reveals a novel mechanism by which vitamin D reduces cardiac injury in prediabetes via the ErbB4/ferroptosis axis.

## Key findings

- Vitamin D supplementation ameliorates cardiac injury and metabolic abnormalities in prediabetic mice.
- Vitamin D inhibits ErbB4 phosphorylation and ferroptosis-related protein expression in the heart.
- Combining vitamin D with an ErbB4 inhibitor provides synergistic protection against cardiac damage.

## Abstract

Vitamin D (VD) deficiency is closely associated with metabolic health and cardiac function in prediabetic patients, yet its underlying mechanisms remain unclear. This study investigated the role of VD intervention in prediabetic cardiac injury through in vivo and in vitro models, with particular focus on the ErbB4/ferroptosis axis. Using a high-fat diet-induced KKAy prediabetic mouse model, we observed significant metabolic abnormalities (increased body weight, hyperglycemia, insulin resistance) and cardiac remodeling (cardiac hypertrophy and functional impairment) (P<0.05). Remarkably, 16-week vitamin D (VD3) supplementation substantially ameliorated these pathological changes and reduced serum cardiac injury markers (P<0.05). Mechanistic studies revealed that VD3 downregulated myocardial NRG1 expression, inhibited ErbB4 phosphorylation (p-ErbB4) and YAP activation (p-YAP), while reversing the abnormal expression of ferroptosis-related proteins. In vitro experiments confirmed that high glucose combined with palmitic acid (HGPA) induced ferroptosis in H9c2 cardiomyocytes, which was alleviated by 1,25(OH)2D3 intervention through suppression of ErbB4 phosphorylation. Notably, combined treatment with 1,25(OH)2D3 and the ErbB4 phosphorylation inhibitor dacomitinib demonstrated synergistic protective effects. Our findings not only expand the understanding of the association between prediabetes and VD, but also reveal a relationship between ErbB4 and cardiac ferroptosis in prediabetic conditions.

## Linked entities

- **Genes:** ERBB4 (erb-b2 receptor tyrosine kinase 4) [NCBI Gene 2066], NRG1 (neuregulin 1) [NCBI Gene 3084], YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413]
- **Proteins:** ERBB4 (erb-b2 receptor tyrosine kinase 4)
- **Chemicals:** 1,25(OH)2D3 (PubChem CID 5280453), dacomitinib (PubChem CID 11511120), palmitic acid (PubChem CID 985)
- **Diseases:** prediabetes (MONDO:0006920), hyperglycemia (MONDO:0002909)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, Tfrc (transferrin receptor) [NCBI Gene 22042] {aka 2610028K12Rik, CD71, E430033M20Rik, Mtvr1, TFR, TFR1}, Ncoa4 (nuclear receptor coactivator 4) [NCBI Gene 27057] {aka ARA70, NCoA-4, Rfg}, Egfr (epidermal growth factor receptor) [NCBI Gene 13649] {aka 9030024J15Rik, Erbb, Errb1, Errp, Wa5, wa-2}, Yap1 (Yes1 associated transcriptional regulator) [NCBI Gene 363014] {aka YAP65, Yap}, Slc7a11 (solute carrier family 7 (cationic amino acid transporter, y+ system), member 11) [NCBI Gene 26570] {aka 9930009M05Rik, sut, xCT}, CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}, Tfrc (transferrin receptor) [NCBI Gene 64678] {aka Trfr}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Nrg1 (neuregulin 1) [NCBI Gene 211323] {aka 6030402G23Rik, ARIA, D230005F13Rik, GGF, GGFII, HRG}, Yap1 (yes-associated protein 1) [NCBI Gene 22601] {aka Yap, Yap65, Yki, Yorkie}, Nrg1 (neuregulin 1) [NCBI Gene 112400], Vdr (vitamin D (1,25-dihydroxyvitamin D3) receptor) [NCBI Gene 22337] {aka Nr1i1}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, NRG1 (neuregulin 1) [NCBI Gene 3084] {aka ARIA, GGF, GGF2, HGL, HRG, HRG1}, Slc7a11 (solute carrier family 7 member 11) [NCBI Gene 310392], Acsl4 (acyl-CoA synthetase long-chain family member 4) [NCBI Gene 113976] {aka Acs4, Facl4}, Lipg (lipase G, endothelial type) [NCBI Gene 16891] {aka 3110013K01Rik, EL, lipase, mEDL}, Erbb4 (erb-b2 receptor tyrosine kinase 4) [NCBI Gene 59323], YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, Gpx4 (glutathione peroxidase 4) [NCBI Gene 625249] {aka GPx-4, GSHPx-4, PHGPx, mtPHGPx, snGPx}, Erbb4 (erb-b2 receptor tyrosine kinase 4) [NCBI Gene 13869] {aka Her4, c-erbB-4}, Acsl4 (acyl-CoA synthetase long-chain family member 4) [NCBI Gene 50790] {aka 9430020A05Rik, ACS4, Facl4, Lacs4}, ERBB4 (erb-b2 receptor tyrosine kinase 4) [NCBI Gene 2066] {aka ALS19, HER4, p180erbB4}, Gpx4 (glutathione peroxidase 4) [NCBI Gene 29328] {aka Gshpx-4, Phgpx, gpx-4, snGpx}
- **Diseases:** dyslipidemia (MESH:D050171), Prediabetic (MESH:D011236), obesity (MESH:D009765), LV mass (MESH:D018487), diabetic heart failure (MESH:D006333), cardiopathy (MESH:C536187), diastolic and (MESH:D006337), cardiomyocyte injury (MESH:D014947), weight gain (MESH:D015430), diabetes (MESH:D003920), hypertrophic (MESH:D002312), cardiac abnormalities (MESH:D018376), myocardial injuries (MESH:D009202), structural abnormalities (MESH:C566527), diabetic cardiac injury (MESH:D058065), hyperglycemia (MESH:D006943), Myocardial hypertrophy (MESH:D006984), hyperlipidemia (MESH:D006949), Cardiovascular complications (MESH:D002318), VD deficiency (MESH:D014808), glucose intolerance (MESH:D018149), LVID;d (MESH:C538319), left ventricular dilation (MESH:C565277), cardiomyocyte death (MESH:D003643), fibrosis (MESH:D005355), hyperinsulinemia (MESH:D006946), metabolic dysregulation (MESH:D021081), inflammation (MESH:D007249), glucolipid metabolism disorders (MESH:D008659), atrial enlargement (MESH:D006332), insulin resistance (MESH:D007333), cardiac dysfunction (MESH:D006331), left ventricular hypertrophy (MESH:D017379), LVID;s (MESH:D010300), metabolic and cardiac abnormalities (MESH:D024821), cardiac remodeling (MESH:D020257)
- **Chemicals:** GSH (MESH:D005978), Hematoxylin (MESH:D006416), paraffin (MESH:D010232), blood glucose (MESH:D001786), DAPI (MESH:C007293), PI (MESH:D010716), ethanol (MESH:D000431), xylene (MESH:D014992), 1,25(OH)2D3 (MESH:D002117), fat (MESH:D005223), polyvinylidene fluoride (MESH:C024865), hydrogen peroxide (MESH:D006861), lipofuscin (MESH:D008062), TG (MESH:D013866), DMEM medium (-), DAB (MESH:C000469), citrate (MESH:D019343), d-glucose (MESH:D005947), Calcein-AM (MESH:C085925), cholesterol (MESH:D002784), methanol (MESH:D000432), Fe (MESH:D007501), saline (MESH:D012965), penicillin (MESH:D010406), lipid peroxides (MESH:D008054), Dac (MESH:C525726), oxygen (MESH:D010100), palmitic acid (MESH:D019308), DCF (MESH:D015649), HG (MESH:D008628), DCFH-DA (MESH:C029569), H&amp;E (MESH:D006371), triglycerides (MESH:D014280), lipid (MESH:D008055), Oil Red O (MESH:C011049), ROS (MESH:D017382), SDS (MESH:D012967), eosin (MESH:D004801), MDA (MESH:D015104), paraformaldehyde (MESH:C003043), DPX (MESH:C027512), PA (MESH:D011478), VD (MESH:D014807), corn oil (MESH:D003314), OCT (MESH:C051883), CO2 (MESH:D002245), Triton X-100 (MESH:D017830), streptomycin (MESH:D013307), Ferrostatin-1 (MESH:C573944), malondialdehyde (MESH:D008315), PBS (MESH:D007854), MC (MESH:C061001), Prussian blue (MESH:C000170), 25(OH)D3 (MESH:D002112), sodium pentobarbital (MESH:D010424), acetic acid (MESH:D019342), water (MESH:D014867)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), HGPA — Trichoplusia ni (Cabbage looper), Spontaneously immortalized cell line (CVCL_C190), H9c2 — Rattus norvegicus (Rat), Spontaneously immortalized cell line (CVCL_0286)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12310489/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12310489/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC12310489/full.md

---
Source: https://tomesphere.com/paper/PMC12310489